Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ibrutinib

FDA-approved product (capsule, oral), marketed as Ibrutinib, Imbruvica.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ibrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Macroglobulinemia
  • Mantle cell lymphoma
  • Neoplasm
  • Waldenstrom macroglobulinemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ibrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ibrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)

    NCT02626884 · start 2016-08

    Registered record
    Registry ID
    NCT02626884
    Conditions
    Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
    Interventions
    Ibrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-08
    Completion
    2020-08
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNodular Lymphocyte-Predominant Hodgkin's Lymphoma
    InterventionIbrutinib
    PhasePhase 2
    Registry statusCompleted

  • Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia

    NCT02827617 · start 2016-06-01

    Registered record
    Registry ID
    NCT02827617
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Ibrutinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-06-01
    Completion
    2024-05-16
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionIbrutinib
    PhaseNot recorded
    Registry statusCompleted

  • Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

    NCT02841150 · start 2016-06

    Registered record
    Registry ID
    NCT02841150
    Conditions
    Healthy
    Interventions
    IMBRUVICA (Treatment A); Ibrutinib (Treatment B)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-06
    Completion
    2016-08
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionIMBRUVICA (Treatment A); Ibrutinib (Treatment B)
    PhasePhase 1
    Registry statusCompleted

  • Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

    NCT02670616 · start 2016-05-01

    Registered record
    Registry ID
    NCT02670616
    Conditions
    Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
    Interventions
    Ibrutinib; Rituximab; Cyclophosphamide; Doxorubicin; vincristine; Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-05-01
    Completion
    2020-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
    InterventionIbrutinib; Rituximab; Cyclophosphamide; Doxorubicin +2 more
    PhasePhase 2
    Registry statusCompleted

  • Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

    NCT02599324 · start 2015-12-01

    Registered record
    Registry ID
    NCT02599324
    Conditions
    Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma; Advanced Gastric Adenocarcinoma; Metastatic Colorectal Adenocarcinoma
    Interventions
    ibrutinib; everolimus; paclitaxel; docetaxel; cetuximab; pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-12-01
    Completion
    2021-08-20
    Enrolment
    263

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma; Advanced Gastric Adenocarcinoma; Metastatic Colorectal Adenocarcinoma
    Interventionibrutinib; everolimus; paclitaxel; docetaxel +2 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

    NCT02562898 · start 2015-10-12

    Registered record
    Registry ID
    NCT02562898
    Conditions
    Metastatic Pancreatic Adenocarcinoma
    Interventions
    Ibrutinib; Paclitaxel; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-10-12
    Completion
    2020-09-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Pancreatic Adenocarcinoma
    InterventionIbrutinib; Paclitaxel; Gemcitabine
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

    NCT02477696 · start 2015-07-28

    Registered record
    Registry ID
    NCT02477696
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Acalabrutinib; Ibrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2015-07-28
    Completion
    2028-01-03
    Enrolment
    533

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionAcalabrutinib; Ibrutinib
    PhasePhase 3
    Registry statusActive not recruiting

  • Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

    NCT02420912 · start 2015-06-19

    Registered record
    Registry ID
    NCT02420912
    Conditions
    Loss of Chromosome 17p; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma; Richter Syndrome
    Interventions
    Ibrutinib; Laboratory Biomarker Analysis; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-06-19
    Completion
    2022-02-14
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLoss of Chromosome 17p; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia +2 more
    InterventionIbrutinib; Laboratory Biomarker Analysis; Nivolumab
    PhasePhase 2
    Registry statusCompleted

  • Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

    NCT02436668 · start 2015-05

    Registered record
    Registry ID
    NCT02436668
    Conditions
    Metastatic Pancreatic Adenocarcinoma
    Interventions
    Ibrutinib; Gemcitabine; Nab-paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-05
    Completion
    2019-04-25
    Enrolment
    430

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Pancreatic Adenocarcinoma
    InterventionIbrutinib; Gemcitabine; Nab-paclitaxel
    PhasePhase 3
    Registry statusCompleted

  • A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

    NCT02403271 · start 2015-03

    Registered record
    Registry ID
    NCT02403271
    Conditions
    Non-Small Cell Lung Cancer; Breast Cancer; Pancreatic Cancer
    Interventions
    Ibrutinib; Durvalumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-03
    Completion
    2017-08
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer; Breast Cancer; Pancreatic Cancer
    InterventionIbrutinib; Durvalumab
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

    NCT02351037 · start 2015-02

    Registered record
    Registry ID
    NCT02351037
    Conditions
    Acute Myeloid Leukemia (AML)
    Interventions
    Ibrutinib; Ibrutinib + LD-AraC; Ibrutinib+Azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-02
    Completion
    2017-04
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia (AML)
    InterventionIbrutinib; Ibrutinib + LD-AraC; Ibrutinib+Azacitidine
    PhasePhase 2
    Registry statusTerminated

  • A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants

    NCT02271438 · start 2014-10

    Registered record
    Registry ID
    NCT02271438
    Conditions
    Healthy
    Interventions
    Ibrutinib; Moxifloxacin; Ibrutinib-matching placebo; Moxifloxacin-matching placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-10
    Completion
    2015-05
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionIbrutinib; Moxifloxacin; Ibrutinib-matching placebo; Moxifloxacin-matching placebo
    PhasePhase 1
    Registry statusCompleted

  • Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression

    NCT02863718 · start 2014-04-30

    Registered record
    Registry ID
    NCT02863718
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Ibrutinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-04-30
    Completion
    2022-07-11
    Enrolment
    515

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionIbrutinib; Placebo
    PhasePhase 3
    Registry statusCompleted

  • ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

    NCT02029443 · start 2014-01-30

    Registered record
    Registry ID
    NCT02029443
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Richter's Syndrome; Prolymphocytic Leukemia
    Interventions
    Acalabrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2014-01-30
    Completion
    2027-06-09
    Enrolment
    306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Richter's Syndrome; Prolymphocytic Leukemia
    InterventionAcalabrutinib
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

    NCT02006485 · start 2013-12-13

    Registered record
    Registry ID
    NCT02006485
    Conditions
    Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma
    Interventions
    Ublituximab + TGR-1202; Ublituximab + TGR-1202 + ibrutinib; Ublituximab + TGR-1202 + bendamustine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-12-13
    Completion
    2019-10
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma
    InterventionUblituximab + TGR-1202; Ublituximab + TGR-1202 + ibrutinib; Ublituximab + TGR-1202 + bendamustine
    PhasePhase 1
    Registry statusCompleted